WHEN TO PARTNER WITH US
We partner at the moments when development decisions matter most—and when the cost of getting them wrong is highest.
When a promising peptide or protein has been identified and the team is preparing to select a radionuclide, chelator, or radiolabeling strategy
Early development choices strongly influence biodistribution, dosimetry, manufacturability, and clinical feasibility. This is often the highest-leverage point to establish a coherent development path.
When preclinical data is emerging and the program needs to translate biological performance into a viable therapeutic profile
Teams may observe strong target binding or tumor uptake, but still need to understand safety margins, dose-limiting organs, and whether the pharmacology supports clinical dosing.
When the program is preparing for IND-enabling studies or regulatory interaction
At this stage, development plans must be technically sound, operationally realistic, and aligned with regulatory expectations. Misalignment here can introduce delays that are difficult and expensive to correct.
When timelines are compressed and execution risk is high
Programs moving quickly toward clinical evaluation often benefit from experienced guidance to coordinate activities across chemistry, pharmacology, manufacturing, and regulatory functions.
When teams recognize that radiopharmaceutical development requires specialized integration across disciplines
Many organizations have strong capabilities in peptide or protein engineering, but limited experience translating those molecules into clinically viable radiopharmaceutical therapies.